Nello Mainolfi - Oct 8, 2021 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Signature
/s/ Bruce Jacobs, as Attorney-in-Fact
Stock symbol
KYMR
Transactions as of
Oct 8, 2021
Transactions value $
-$2,604,696
Form type
4
Date filed
10/12/2021, 04:30 PM
Previous filing
Aug 19, 2021
Next filing
Dec 16, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYMR Common Stock Options Exercise $86.4K +41.5K +8.95% $2.08* 506K Oct 8, 2021 Direct
transaction KYMR Common Stock Sale -$1.18M -21.2K -4.2% $55.56 485K Oct 8, 2021 Direct F1, F2
transaction KYMR Common Stock Sale -$532K -9.37K -1.93% $56.82 475K Oct 8, 2021 Direct F1, F3
transaction KYMR Common Stock Sale -$119K -2.08K -0.44% $57.29 473K Oct 8, 2021 Direct F1, F4
transaction KYMR Common Stock Sale -$469K -7.92K -1.67% $59.28 465K Oct 8, 2021 Direct F1, F5
transaction KYMR Common Stock Sale -$40.4K -670 -0.14% $60.32 464K Oct 8, 2021 Direct F1, F6
transaction KYMR Common Stock Sale -$16.8K -271 -0.06% $61.87 464K Oct 8, 2021 Direct F1
transaction KYMR Common Stock Options Exercise $13.4K +6.46K +1.39% $2.08* 471K Oct 11, 2021 Direct
transaction KYMR Common Stock Sale -$306K -5.71K -1.21% $53.58 465K Oct 11, 2021 Direct F1, F7
transaction KYMR Common Stock Sale -$40.5K -744 -0.16% $54.50 464K Oct 11, 2021 Direct F1, F8

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYMR Stock Option (Right to Buy) Options Exercise $0 -41.5K -54.15% $0.00 35.2K Oct 8, 2021 Common Stock 41.5K $2.08 Direct F9
transaction KYMR Stock Option (Right to Buy) Options Exercise $0 -6.46K -18.35% $0.00 28.7K Oct 11, 2021 Common Stock 6.46K $2.08 Direct F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.10 to $56.09. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.19 to $57.185. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.20 to $58.14. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.90 to $59.81. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F6 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.91 to $60.61. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F7 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.19 to $54.16. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F8 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.28 to $54.60. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F9 The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones.